Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Shareholder vote
confidence 92%
filed 2026-08-20
EX-99.1
This exhibit discloses the results of an Ordinary and Extraordinary General Shareholders' Meeting held on August 20, 2026, where shareholders approved multiple material resolutions including: (1) bylaw amendments, (2) a merger with Inversiones y Técnicas Aeroportuarias resulting in issuance of approximately 7.2 million new shares (a ~2.4% dilution to the current 300 million share base), and (3) two extraordinary dividends of Ps. 10.00 per share payable in November and December 2026. The disclosure explicitly reports shareholder approval of these matters, fitting the definition of shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-20
Item 5.07
Quoin Pharmaceuticals held its Annual Meeting of shareholders on August 20, 2026, with voting results on five proposals: election of seven directors, advisory approval of named executive officer compensation, approval of non-employee director compensation changes, approval of 401(k) matching contribution changes, and appointment of the independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
Item 5.07
This Item 5.07 disclosure reports the results of a stockholder vote at FS KKR Capital Corp.'s reconvened Annual Meeting held on August 20, 2026. The filing presents the final voting tallies for Proposal No. 2 (the Share Issuance Proposal), which sought stockholder approval to allow the Company to sell shares below net asset value per share. The proposal was approved with 103,799,016 votes in favor versus 35,494,986 against, meeting both the majority-of-outstanding-shares and majority-of-non-affiliated-shares thresholds required under the Investment Company Act of 1940. This is a material governance event affecting the Company's future capital-raising flexibility.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
Item 5.07
Sono Tek Corp held its annual shareholder meeting on August 20, 2026, at which shareholders elected three directors (Eric Haskell, Adeniyi Lawal, and Carol O'Donnell) by plurality vote and ratified CBIZ CPAs P.C. as independent auditors for fiscal year 2027.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
Item 5.07
LivePerson held a special stockholder meeting on August 20, 2026, to vote on the proposed merger with SoundHound AI. The Adjournment Proposal was approved with 5,811,286 shares in favor versus 193,675 against, and the meeting was adjourned to September 2, 2026, to solicit additional proxies for the Merger Proposal, which had received over 97% support to date.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-20
The 6-K discloses results of an Extraordinary General Meeting of Shareholders held on August 20, 2026, with voting outcomes on three proposals: (1) a 50-for-1 share consolidation and corresponding changes to authorized capital, (2) adoption of sixth amended and restated memorandum and articles of association reflecting the consolidation and governance amendments, and (3) adjournment authority. All three proposals were approved by shareholders with substantial majorities. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it fundamentally alters share structure and par value.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-20
Item 5.07
This is a clear disclosure of shareholder voting results from Oxford Square Capital Corp.'s Annual Meeting of Stockholders held on August 20, 2026. The filing reports final voting tabulations for two proposals: (1) election of two directors (Steven P. Novak and Charles M. Royce) for three-year terms, and (2) ratification of Ernst & Young LLP as independent auditor. The voting counts, quorum confirmation, and record date are all provided, matching the standard format for Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
Item 5.07
This Item 5.07 disclosure reports the results of a Special Meeting of Stockholders held on August 18, 2026, where shareholders voted on three proposals: ratification of a 77.4 million CDI issuance, approval of a 92.1 million CDI issuance to BCP3 Pty Ltd associates, and adjournment authority. All three proposals passed. The disclosure includes vote tallies (For, Against, Abstain, Broker Non-Vote, Uncast) for each proposal, which is the core content of a shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
The filing discloses results of Interpace Biosciences' 2026 annual meeting of stockholders held on August 20, 2026, with voting outcomes on seven proposals including approval of an amended certificate of incorporation, reverse stock split authorization, equity and employee stock purchase plans, director elections, executive compensation advisory vote, and auditor ratification. This is a classic Item 5.07 shareholder vote results disclosure with detailed vote tallies for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-20
Item 5.07
This is a clear disclosure of shareholder vote results from RCI Hospitality Holdings' Annual Meeting of Stockholders held on August 20, 2026. The filing reports voting outcomes on three matters: election of six directors (Item 1), ratification of CBIZ CPAs P.C. as independent auditor (Item 2), and approval of a non-binding advisory resolution on executive compensation (Item 3), with detailed vote tallies for each. This is a quintessential Item 5.07 disclosure and material to investors as it reflects governance decisions and shareholder approval of key corporate matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-20
Item 5.07
This is a clear disclosure of shareholder vote results from NeOnc Technologies' 2026 annual meeting held on August 14, 2026. The filing reports final voting tallies on four proposals: election of two Class I directors (Victoria Medvec and Steven L. Giannotta), amendment of the 2023 Equity Incentive Plan, ratification of CBIZ CPAs P.C. as independent auditor, and adjournment authority. All proposals passed with substantial majorities. This is a material governance event affecting investor understanding of board composition and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
The filing discloses results of an extraordinary general meeting held on August 19, 2026, where RF Acquisition Corp II shareholders voted on six proposals, including approval of a business combination with Nanyang Biologics Pte. Ltd. Item 5.07 reports detailed voting results for each proposal (Business Combination Proposal, Merger Proposal, Advisory Governance Proposals, Nasdaq Proposal, Incentive Plan Proposal, and Adjournment Proposal), with the Business Combination Proposal receiving 6,765,584 votes in favor and 440,604 against. This is a material shareholder vote on a significant M&A transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from World Acceptance Corporation's Annual Meeting held on August 19, 2026. The filing reports final voting tallies for three proposals: election of six directors, advisory vote on executive compensation, and ratification of the independent auditor (RSM US LLP). The detailed vote counts for each director and proposal are the core content of the disclosure, making this unambiguously a shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
Item 5.07
Microchip Technology held its annual stockholder meeting on August 18, 2026, with voting results reported for director elections (seven nominees), equity plan amendment approval, auditor ratification, and advisory compensation vote, presented with tabulated vote counts for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
Item 5.07
This Item 5.07 discloses the results of Eagle Nuclear Energy Corp.'s 2026 annual meeting of shareholders held on August 19, 2026, specifically the election of two Class I directors (Brian Goldmeier and Ron Bloom) with detailed vote tallies. The filing presents the voting results in the standard format required for shareholder vote disclosures, making this a clear and unmistakable shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
Item 5.07
TuHURA Biosciences held its 2026 Annual Meeting of Stockholders on August 18, 2026, with all six proposals passing by requisite majorities: election of six directors (James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler), approval of Nasdaq-required share issuance, advisory vote on executive compensation, say-on-frequency vote, auditor ratification, and adjournment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
Item 5.07
CalciMedica held its Annual Meeting on July 23, 2026, and shareholders voted on eight proposals including director elections, auditor ratification, an equity plan amendment increasing authorized shares by 7.5 million, say-on-pay votes, a reverse stock split, and two material warrant issuances involving up to approximately 37.3 million shares of potential dilution.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-19
Item 5.07
This is a clear disclosure of shareholder vote results from the August 18, 2026 annual meeting under Item 5.07. The filing reports voting outcomes for five proposals: election of six directors (Proposal 1), ratification of auditor dbbmckennon (Proposal 2), approval of the 2026 Equity Incentive Plan (Proposal 4), and approval of adjournment authority (Proposal 5), with Proposal 3 (Charter Amendment) deferred to September 16, 2026 due to insufficient votes. The detailed vote tallies for each proposal and director candidate are provided, making this a standard shareholder vote results disclosure material to investors assessing governance and capital allocation decisions.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-08-19
The 6-K discloses the outcome of an Extraordinary General Meeting held on August 18, 2026. Although no resolutions were voted upon due to failure to achieve the required quorum (one-half of issued and outstanding voting shares), the disclosure of a failed EGM and the Board's decision not to adjourn it constitutes a shareholder-vote-related event. The failure to achieve quorum and the Board's decision to conclude the meeting without adjournment are material governance outcomes that would affect investor assessment of the Company's ability to conduct shareholder business.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-19
Item 5.07
This Item 5.07 disclosure reports the results of Forum Markets' 2026 Annual Meeting of Stockholders held on August 19, 2026, including voting outcomes on three proposals: election of three Class II directors (McAndrew Rudisill, Ryan Smith, and Jason New), advisory approval of named executive officer compensation, and ratification of M&K CPAS, PLLC as independent auditors. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
This 8-K discloses the results of Glucotrack's August 18, 2026 annual meeting of stockholders under Item 5.07, reporting voting outcomes on five proposals: election of six directors, advisory say-on-pay vote, auditor ratification, reverse stock split approval, and warrant inducement approval. The filing presents detailed vote tallies (for, against, abstentions, broker non-votes) for each proposal, which is the core content and purpose of the disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-19
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Focus Universal Inc.'s 2026 annual meeting of stockholders held on August 18, 2026. The filing presents voting results for four proposals: election of five directors, ratification of the independent auditor (Weinberg & Company, P.A.), approval of up to $250 million in securities issuances, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal are the core content of this Item 5.07 disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-08-19
Item 5.07
Item 5.07 requires disclosure of shareholder vote results. Although this filing reports a failed quorum rather than completed voting results, it discloses the outcome of a stockholder meeting submission — specifically that the adjourned Special Meeting on August 19, 2026 lacked the required quorum (1,157,852 shares needed; only 3,473,554 shares outstanding) and was cancelled without further proxy solicitation. This is a material governance event affecting the Company's ability to conduct shareholder business.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
Item 5.07
Nextpower Inc. held its Annual Meeting on August 18, 2026, with shareholders voting on four proposals: election of Class I directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and amendments to the Certificate of Incorporation. The filing discloses detailed voting results for each proposal.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 75%
filed 2026-08-18
EX-99.1
The exhibit reports results of bondholders' meetings held on August 18, 2026, for two domestic debt issuances (2010 and 2013). The 2010 meeting failed to achieve quorum, and the 2013 meeting achieved only 15.33% quorum—both falling short of the 80% principal amount required under Colombian law to approve a merger proposal. A second-call meeting is required. While technically a bondholder vote rather than shareholder vote, this disclosure of voting results on a material corporate action (merger) affecting debt holders is analogous to shareholder vote results and material to investors assessing the company's capital structure and M&A progress.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from J. M. Smucker's Annual Meeting of Shareholders held August 12, 2026. The filing reports final voting tallies on three matters: election of eleven directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation. All three are routine annual meeting matters with clear vote counts presented in tabular form.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-17
EX-99.1
The exhibit announces results of an extraordinary general meeting held on August 14, 2026, where shareholders passed resolutions to increase authorized share capital, consolidate shares at a 700:1 ratio, and cancel fractional shares. This is a direct disclosure of shareholder vote results on material capital structure changes, matching the `shareholder_vote_results` taxonomy entry. The share consolidation and authorized capital increase are material to investors' assessment of share structure and dilution.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
LiveRamp stockholders voted at a Special Meeting on August 17, 2026, approving seven proposals including a merger agreement with Publicis Groupe (via MMS USA Holdings and Merger Sub), director elections, equity plan amendments, say-on-pay votes, and auditor ratification. The merger proposal received overwhelming approval with 51.6M votes in favor versus 60K against.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This Item 5.07 filing discloses the results of the 2026 Annual Meeting of Stockholders held on August 12, 2026, including voting outcomes for two proposals: (1) election of four directors to one-year terms, with detailed vote tallies for each nominee (Jerome S. Flum, Lisa Reisman, Joshua M. Flum, and Lawrence Fensterstock), and (2) ratification of CohnReznick LLP as independent auditor, with 7,751,920 votes for and 14,945 against. This is a textbook shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Aardvark Therapeutics' 2026 Annual Meeting of Stockholders held on August 14, 2026. The filing presents voting outcomes for three proposals: election of two Class I directors (Victor Tong, Jr. and Jeffrey Chi, Ph.D.), ratification of BDO USA, P.C. as independent auditor, and approval of stock option repricing under three equity plans. All three proposals passed. This is material as shareholder votes on director elections, auditor ratification, and equity compensation arrangements directly affect investor assessment of governance and capital structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-17
The 6-K discloses results of an Annual and Special General Meeting of Shareholders held on August 17, 2026, where shareholders voted on and approved seven proposals including auditor re-appointment, director re-elections, and executive compensation arrangements. This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, covering material governance and compensation matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-17
Item 5.07
Silo Pharma held its annual shareholder meeting on August 14, 2026, with voting results on four proposals: election of four directors (all approved), ratification of Salberg & Company as auditor (approved), authorization to increase authorized common shares from 6.67 million to 250 million shares (approved with 498,224 votes for and 190,599 against), and meeting adjournment authority (approved). The substantial increase in authorized shares represents a material expansion of the company's equity issuance capacity and potential dilution.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-17
The 6-K furnishes a "Consolidated Synthetic remote voting map" disclosing the results of an Extraordinary General Meeting held on August 18, 2026. The document presents voting tallies on seven items including the number of Board members, nomination and election of directors (Daniel Barriuso Rojo and Gilson Finkelsztain), and confirmation of Board composition. This is a direct disclosure of shareholder vote results as required by CVM Resolution No. 81/22, matching the `shareholder_vote_results` taxonomy type.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-17
The filing discloses results of a Special Meeting of stockholders held on August 13, 2026, where shareholders voted on a Charter Amendment Proposal to extend the Business Combination Period by nine months (from August 18, 2026 to May 18, 2027). The proposal received 3,904,200 affirmative votes representing 96.1% of outstanding shares, exceeding the 65% approval threshold required. Item 5.07 explicitly reports submission of matters to a vote of security holders and the voting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This Item 5.07 disclosure reports the results of CEL-SCI's annual shareholder meeting held on August 14, 2026, including election of three directors (Geert Kersten, Bruno Baillavoine, Robert Watson) and approval of six proposals: adoption of the 2026 Non-Qualified Stock Option Plan, adoption of the 2026 Stock Bonus Plan, advisory vote on executive compensation, advisory vote frequency, and ratification of BDO USA, LLP as independent auditor. The tabulation of votes cast for each proposal is provided in full, which is the core disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
This Item 5.07 disclosure reports the results of CytoSorbents' 2026 Annual Meeting of Stockholders held on August 13, 2026, including voting outcomes on five proposals: election of five directors, advisory approval of named executive officer compensation, ratification of the independent auditor (WithumSmith+Brown, PC), approval of a reverse stock split (1-for-5 to 1-for-20 ratio), and approval of an adjournment provision. All proposals passed. The disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-14
Item 5.07
RE/MAX Holdings shareholders approved two material merger proposals at a special meeting held on August 14, 2026: approval of issuance of Class A common stock to RIHI stockholders (26,660,357 votes for, 169,623 against) and adoption of the Merger Agreement with The Real Brokerage Inc. (26,681,107 votes for, 149,866 against), creating the combined 'Real REMAX Group' entity. Shareholders of both Real and RE/MAX Holdings approved the transaction, with Real shareholders voting approximately 99.0% in favor and RE/MAX Holdings shareholders voting 78.8% of voting power in favor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
PDS Biotechnology held its Annual Meeting of Stockholders with voting results on four proposals: election of two Class B directors (Kamil Ali-Jackson and Ilian Iliev), approval of a Certificate of Incorporation amendment to increase authorized common shares, ratification of KPMG as independent auditor, and a non-binding advisory vote on named executive officer compensation.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-14
The 6-K discloses results of an Extraordinary General Meeting held on August 14, 2026, where shareholders voted on and approved two material proposals: (1) a 1-for-5 consolidation of Class A and Class B ordinary shares, and (2) authorization for a further consolidation at a ratio between 1-for-2 and 1-for-10 to be determined by the board by February 10, 2027. The filing provides detailed voting tallies for each proposal, including vote counts and percentages for both share classes. This is a classic shareholder vote result disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it affects share structure and ownership percentages.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses results of a Special Meeting of Stockholders held on August 13, 2026, where shareholders voted on two proposals: (1) approval of a reverse stock split authorization (1-for-2 to 1-for-8 ratio, to be determined by the Board), which passed with 49,401,476 votes for vs. 10,935,417 against, and (2) an adjournment proposal, which also passed. This is a classic Item 5.07 shareholder vote results disclosure. The reverse stock split authorization is material to investors as it affects share structure and is typically undertaken to address delisting risks or improve stock price perception.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses Item 5.07 results from a special stockholder meeting held on August 14, 2026, where shareholders voted on a reverse stock split proposal (approved 3,847,974 to 1,062,981) and an adjournment proposal. The reverse stock split authorization at a 1-for-2 to 1-for-50 ratio is material to investors as it directly affects share structure and is typically a signal of delisting risk mitigation or capital restructuring.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses Item 5.07 — submission of matters to a vote of security holders. The Majority Stockholder (Rennova Health, Inc., controlled by the CEO) approved by written consent an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio of 1:50 to 1:1,000, with the exact ratio to be determined by the Board solely for purposes of facilitating an uplisting to Nasdaq or NYSE American. This is a material shareholder action affecting capital structure and listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses results of GT Biopharma's Annual Meeting of Stockholders held on August 14, 2026, under Item 5.07. Six proposals were voted upon: election of four directors, ratification of auditors (Weinberg & Company, P.A.), advisory approval of executive compensation, approval of a reverse stock split (1-for-10 to 1-for-30 ratio) with authorized share reduction, and two amendments to the 2022 Omnibus Incentive Plan. All proposals passed. The reverse stock split authorization and equity plan amendments are material governance and capital structure decisions affecting shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
Item 5.07 discloses the results of the 2026 Annual Meeting of Shareholders held on August 12, 2026, including voting results for the election of trustee Steven S. Robson (7,090,809 votes for) and ratification of BCRG Group as independent auditors (7,447,535 votes for). This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
Item 5.07
This 8-K Item 5.07 discloses the results of a special meeting of stockholders held on August 13, 2026, where shareholders voted on a proposal to authorize the Company to issue shares of common stock below net asset value (up to 25% of outstanding shares) for a twelve-month period. The vote tabulation shows the proposal was approved with 287.2 million votes in favor versus 70.1 million against. This is a material shareholder vote result that grants significant capital-raising authority to management.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 25%
filed 2026-08-14
EX-99.1
This is a 2026 proxy statement soliciting shareholder votes on five proposals at the Annual General Meeting scheduled for September 18, 2026. The document is not reporting results of a vote that has already occurred; rather, it is requesting shareholder approval in advance of the meeting. The most material proposal is Proposal 4, which seeks shareholder approval to issue approximately 11.58 million new Butterfield shares (39% of the $1.794 billion purchase price) in connection with the acquisition of CIBC Caribbean. However, since this is a proxy statement soliciting votes rather than disclosing vote results, the proper classification is ambiguous—the exhibit is neither a discrete event nor a periodic report, but rather a governance document requesting shareholder action on a material M&A transaction.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-14
The 6-K discloses the results of an extraordinary general meeting of shareholders held on August 10, 2026, with voting outcomes on three resolutions: (1) approval of a 100x increase in authorized share capital from 50 million to 5 billion shares; (2) creation of dual-class shares (Class A with 1 vote, Class B with 50 votes) and adoption of amended articles; and (3) a 6-for-1 share consolidation effective October 7, 2026. All three resolutions passed with overwhelming majorities (99.7%+). These governance and capital structure changes are material to investors' assessment of voting rights, ownership dilution, and control dynamics.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
Owlet held its Annual Meeting of Stockholders on June 15, 2026, and reported final voting results for five proposals: election of directors Marc F. Stoll and Kurt Workman, advisory vote on named executive officer compensation (approved), annual frequency for say-on-pay votes, ratification of PricewaterhouseCoopers LLP as auditor, and approval of Amendment No. 3 to the 2021 Incentive Award Plan increasing the equity share pool by 600,000 shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-08-14
Item 5.07
Shareholders approved three proposals at a meeting: an Articles Amendment, a Trust Agreement Amendment extending the business combination deadline to February 15, 2027, and an Adjournment Proposal. The vote also resulted in 833,157 ordinary shares being redeemed, removing approximately $9.3 million from the Trust Account.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-13
Item 5.07
Results of the Annual Meeting of Shareholders held on August 11, 2026, including election of eight directors to the Board, advisory vote on named executive officer compensation, and ratification of PricewaterhouseCoopers, LLP as independent auditor.
View raw filing on EDGAR →